Abstract
Background: Intensive efforts have been implemented to improve the efficacy of platinum complexes especially with emerging cisplatin resistance and elevated cancer deaths. Platinum(IV) agents show better pharmacokinetics and decreased side effects compared to Platinum(II) agents.
Methods: This review aims to summarize and categorize the strategies being employed to improve the efficacy of Platinum-based anticancer agents in recent years. Results: Nanoparticles and nanoplatforms offer a vast variety of strategies in targeting specific tumor types and delivering one or two lethal drugs simultaneously. Theranostic agents are being developed to achieve enhanced imaging and provide further insight into the activity of platinum containing chemotherapy. Moreover, photoactivation of Pt(IV) prodrugs specifically at the tumor site is gaining attention due to a controlled activity. A platinum agent formulated as large multi-activity complex is the most common strategy being employed. Conclusion: Platinum(IV) agents offer great potential in targeting, increasing efficacy, and decreasing toxicity of Platinum-based anticancer agents. The strategies being employed are aiming to increase specificity and targeting as well as provide more potent agents.Keywords: Pt(IV), chemotherapy, nanoparticles, prodrugs, targeted delivery, theranostic, photoactivatable.
Current Pharmaceutical Design
Title:Recent Approaches to Platinum(IV) Prodrugs: A Variety of Strategies for Enhanced Delivery and Efficacy
Volume: 23 Issue: 16
Author(s): Anas Najjar, Naeema Rajabi and Rafik Karaman*
Affiliation:
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Al-Quds University, P.O. Box 20002, Jerusalem,Italy
Keywords: Pt(IV), chemotherapy, nanoparticles, prodrugs, targeted delivery, theranostic, photoactivatable.
Abstract: Background: Intensive efforts have been implemented to improve the efficacy of platinum complexes especially with emerging cisplatin resistance and elevated cancer deaths. Platinum(IV) agents show better pharmacokinetics and decreased side effects compared to Platinum(II) agents.
Methods: This review aims to summarize and categorize the strategies being employed to improve the efficacy of Platinum-based anticancer agents in recent years. Results: Nanoparticles and nanoplatforms offer a vast variety of strategies in targeting specific tumor types and delivering one or two lethal drugs simultaneously. Theranostic agents are being developed to achieve enhanced imaging and provide further insight into the activity of platinum containing chemotherapy. Moreover, photoactivation of Pt(IV) prodrugs specifically at the tumor site is gaining attention due to a controlled activity. A platinum agent formulated as large multi-activity complex is the most common strategy being employed. Conclusion: Platinum(IV) agents offer great potential in targeting, increasing efficacy, and decreasing toxicity of Platinum-based anticancer agents. The strategies being employed are aiming to increase specificity and targeting as well as provide more potent agents.Export Options
About this article
Cite this article as:
Najjar Anas, Rajabi Naeema and Karaman Rafik*, Recent Approaches to Platinum(IV) Prodrugs: A Variety of Strategies for Enhanced Delivery and Efficacy, Current Pharmaceutical Design 2017; 23 (16) . https://dx.doi.org/10.2174/1381612823666170201161037
DOI https://dx.doi.org/10.2174/1381612823666170201161037 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fusogenic Oncolytic Herpes Simplex Viruses as a Potent and Personalized Cancer Vaccine
Current Pharmaceutical Biotechnology Use of the Non-Toxic Cryoprotectant Trehalose Enhances Recovery and Function of Fish Embryonic Stem Cells Following Cryogenic Storage
Current Stem Cell Research & Therapy From Protein Communication to Drug Discovery
Current Topics in Medicinal Chemistry Biomarkers for Systemic Therapy in Ovarian Cancer
Current Cancer Drug Targets In Vitro Antitumoral Activity of Palladium(II) and Platinum(II) Complexes with O,O'-Dialkyl Esters of Ethylene-bis(S)-Leucine
Letters in Drug Design & Discovery Management of Advanced Staged Ovarian Cancer in a National Cancer Center: Comparison of the Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy
Current Women`s Health Reviews Therapeutic Potential of HDAC Inhibitors in the Treatment of Cardiac Diseases: A Short Review
Current Drug Targets Discovery of the Aminated Quinoxalines as Potential Active Molecules
Letters in Drug Design & Discovery MiRNAs in Human Cancers: The Diagnostic and Therapeutic Implications
Current Pharmaceutical Design Novel Chemotherapeutic Agents - The Contribution of Scorpionates
Current Medicinal Chemistry Pre-clinical Validation of Mito-targeted Nano-engineered Flavonoids Isolated From Selaginella bryopteris (Sanjeevani) As A Novel Cancer Prevention Strategy
Anti-Cancer Agents in Medicinal Chemistry Raloxifene and Cardiovascular Health: Its Relationship to Lipid and Glucose Metabolism, Hemostatic and Inflammation Factors and Cardiovascular Function in Postmenopausal Women
Current Pharmaceutical Design Breast Cancer: Not Only a “Womans” Disease
Current Women`s Health Reviews Medicinal Research Progress of Natural Coumarin and its Derivatives
The Natural Products Journal Molecular Markers of Angiogenesis and Metastasis in Lines of Oral Carcinoma after Treatment with Melatonin
Anti-Cancer Agents in Medicinal Chemistry Biomimetic Drug Delivery Systems Oriented by Biological Function in Tumor Targeting
Current Drug Targets Knocking Down Gene Expression with Dendritic Vectors
Mini-Reviews in Medicinal Chemistry In Vivo Inhibition of the Estrogen Sulfatase Enzyme and Growth of DMBA-Induced Mammary Tumors by Melatonin
Current Cancer Drug Targets Based on Nucleotides Analysis of Tumor Cell Lines to Construct and Validate a Prediction Model of Mechanisms of Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Anti-Cancer / Anti-Tumor
Current Bioactive Compounds